Investment Pitches

Pitch Summary:
KGHM was included for its strong position in copper and silver. The stock was sold with the commodity pillar's dissolution, but patience could have captured more gains.

BSD Analysis:
KGHM was part of the commodity pillar due to its strong positioning in copper and silver. The stock was sold when the pillar was dissolved, but the largest part of the price increase occurred afterward, suggesting that more patience could have yielded higher returns. The company remains a potential candidate if the commodity pillar is re-established.

Pitch Summary:
GPW was bought for its defensive business model and low valuation. The stock remains attractive due to accelerated growth and favorable regulatory changes.

BSD Analysis:
GPW was selected for its stable business model and attractive valuation. The company's growth has accelerated since the initial analysis, and new laws promoting the capital market are expected to benefit GPW in the medium term. The stock remains one of the highest-weighted positions in the portfolio.

Pitch Summary:
Grupo Mexico was pitched as a play on reducing NAV discount and rising copper prices. Both elements of the thesis materialized, leading to a successful investment.

BSD Analysis:
Grupo Mexico was part of a strategy to capitalize on the reduction of NAV discount and the rising copper prices. The investment thesis was validated as both factors played out, resulting in a profitable exit. The position was sold with the dissolution of the commodity pillar, but the company remains a potential candidate if the pillar is re-established.

Pitch Summary:
Kaspi faced challenges due to rising inflation and interest rates in Kazakhstan, along with regulatory headwinds, leading to a negative stock performance.

BSD Analysis:
Kaspi's stock performance was negatively impacted by macroeconomic factors in Kazakhstan, including rising inflation and interest rates, which contrasted with global trends. Regulatory challenges further pressured the stock, resulting in mixed financial results. A rebound was utilized for exit, but the stock remains under observation for potential re-entry if conditions improve.

Pitch Summary:
Inter&co was identified as undervalued compared to Nubank, with significant potential for price appreciation. The stock price increased by 118% over 10 months, reducing the valuation gap with Nubank.

BSD Analysis:
Inter&co was pitched as undervalued compared to Nubank, with a market cap disparity suggesting significant upside. Over 10 months, Inter&co's price rose by 118%, narrowing the valuation gap from 28x to 18x relative to Nubank. The stock remains in the portfolio due to continued upside potential.

Pitch Summary:
Nürnberger Beteiligungen was initially bought for fundamental reasons but quickly became an acquisition case. The stock was sold after takeover speculation at €65, although the final offer exceeded expectations at €120.

BSD Analysis:
The investment in Nürnberger Beteiligungen was initially based on fundamental valuation, but it turned into an acquisition play. The stock was sold at €65 due to uncertainty about the offer structure, but the final acquisition price of €120 was significantly higher than the initial target, indicating a missed opportunity.

Pitch Summary:
B3 was pitched due to its attractive valuation compared to peers, despite high interest rates in Brazil. The stock is not currently in the portfolio but remains a candidate if conditions improve.

BSD Analysis:
B3's valuation is attractive compared to its peers, but high interest rates in Brazil (15%) impact its relative valuation. The stock was in the portfolio twice within a year but is not currently held. A potential re-entry could occur if the stock price declines further or if Brazilian interest rates decrease.

Pitch Summary:
Hellenic Exchanges was pitched as an investment due to its fundamental revaluation and the potential for an acquisition. The investment thesis was validated with an acquisition offer, although the offer price was considered low.

BSD Analysis:
The investment in Hellenic Exchanges was driven by the expectation of a fundamental revaluation and a potential acquisition. The acquisition offer confirmed the thesis, but the offer price was lower than anticipated, partly due to the payment in Euronext shares, which declined in value. The position was sold after the offer, but the stock remains a potential buy if the offer is rejected.

Pitch Summary:
Jose Cuervo is an attractive investment due to its strong market position as the leading tequila brand, its growth in premium tequila segments, and its low leverage. Despite challenges in the US market, the company's growth in other regions and its efficient capital allocation by management make it a compelling opportunity.

BSD Analysis:
Jose Cuervo's financial metrics, such as an EV/EBIT of 10.5 and an EV/EBITDA ratio of 9.1, indicate an attractive valuation. The company's tequila portfolio has shown significant growth, with super-premium brands like 1800 and Centanario doubling in volume over the past five years. The management's strategic decisions, including asset sales and debt reduction, highlight their capability as effective capital allocators. While the US market presents challenges due to economic conditions, Cuervo's strong position in Mexico and other regions provides a buffer. The company's low leverage, with a net debt of 9 billion pesos, further strengthens its financial stability.

Pitch Summary:
Following the announcement of additional tariffs by former U.S. President Donald Trump, shares of FIT Hon Teng (6088 HK), the Foxconn-backed interconnect solutions provider, experienced a sharp sell-off. The stock price fell from HK$3.80 to HK$1.80 in the aftermath, reflecting investor concerns over potential supply chain disruptions and margin pressures tied to U.S.-China trade tensions. From mid to late May, we initiated and built a position in the company at an average entry price of HK$2.10. Our investment decision was based on the view that tariff-related weakness had largely been priced in, while the company continued to exhibit solid long-term fundamentals. FIT Hon Teng is strengthening its position in high-speed interconnects, optical modules, and electric vehicle connectors—segments we believe will benefit from structural growth drivers regardless of short-term geopolitical noise. The company also stands to benefit from the ramp-up in NVIDIA’s GB200 servers, with its AI server business potentially contributing a low double-digit percentage of earnings in FY25. The stock’s retracement provided an attractive entry point relative to historical valuation multiples and peer group comparisons. We saw upside potential as the market reassessed the durability of FIT Hon Teng’s business model and its ability to navigate shifting trade policies. This made our purchase at HK$2.10 a compelling risk-reward proposition at 6–7x FY26e P/E. We subsequently realized gains on the bulk of our position, selling between HK$3.90 and HK$5.90, as the market re-rated the stock to higher earnings multiple. :contentReference[oaicite:4]{index=4}

BSD Analysis:
FIT Hon Teng has seen its stock price surge by over forty percent in the past year, reflecting investor confidence in a major earnings turnaround led by the global AI server buildout. While historical profits have been under pressure due to a shift in the consumer electronics cycle, analysts are forecasting a significant thirty percent annual growth in earnings over the next three years. This optimism is centered on the company’s role as a key component supplier for AI-related infrastructure and its increasing integration into the broader Foxconn ecosystem. Although the current price-to-earnings ratio appears elevated, it is supported by an earnings outlook that is expected to decidedly outshine the broader Hong Kong market. As the firm transitions toward higher-value interconnect solutions for data centers, FIT Hon Teng represents a high-beta recovery play on the industrial AI cycle.

Pitch Summary:
Cheerwin is a leading platform in China offering a comprehensive range of products across household care, personal care, and pet categories. The company develops and manufactures a broad portfolio spanning household repellents, insecticides, cleaning agents, and air care products, and holds the top market share across several subsegments. Currently, over 90% of revenue is derived from core household product categories, while its pet segment—including 77 retail stores—contributes around 7% of group revenue. This pet business is expected to expand and serve as a growth driver, potentially accounting for 10% of total revenue in the coming year. Gross margin improved from 45.0% in 2023 to 49.2% in 2024, with scope for further upside. At present, 37% of sales are generated online and 63% offline. Online sales deliver a significantly higher gross margin of 55.8%, compared with 45.2% for offline. As the business continues to shift toward online distribution, the company’s overall margin profile should strengthen accordingly. Group revenue is expected to grow at ~8–10% annually, with PATMI rising at a similar or slightly higher pace. With no debt on the balance sheet, Cheerwin maintains a strong net cash position of RMB2.65bn versus a market capitalization of HK$2.93bn (RMB2.69bn). At the current share price of HK$2.20, and assuming an 80% payout ratio, the dividend yield in FY25e/26e is projected at 6.7% and 7.3%, respectively. From a valuation perspective, stripping out interest income from its net cash, Cheerwin generated RMB158mn of core operating profit in 2024. Applying a 10–12x EV/EBIT multiple (a ~30% discount to peers) on FY26e core operating profit of RMB210mn, and applying a 20% discount to net cash, we derive a fair value per share of HK$3.45–3.80. This implies 57–73% upside, corresponding to FY26e P/E of 17.2x–18.9x and dividend yields of 4.7%–4.2%. :contentReference[oaicite:3]{index=3}

BSD Analysis:
Cheerwin Group holds a dominant position in the Chinese household products market, maintaining top-tier offline market share in essential categories like mosquito repellents and disinfectants. The company is currently trading at a significant discount to its estimated fair value, offering a compelling entry point for value-oriented investors as earnings are forecast to grow by over fourteen percent annually. Despite a more conservative dividend policy compared to previous years, the firm’s low price-to-earnings ratio and stable weekly volatility make it a resilient defensive holding. Management is focusing on product innovation under its core brands like Babeking and Superb to capture a larger share of the premiumizing domestic consumer market. With low debt and a strong cash position, Cheerwin is well-positioned to navigate near-term economic fluctuations while maintaining its market leadership.

Pitch Summary:
Historically, alternative asset managers primarily served institutional investors (sovereign wealth funds, pension funds etc.) seeking exposure to alternative assets. However, individual investors, from high-net-worth individuals to mass-affluent clients, are now increasingly interested in this asset class (private equity, infrastructure, credit etc.), creating a market potentially as large as the institutional segment. The industry is also now on the cusp of being able to sell products to the 401(k) market, which holds an estimated $7 trillion in assets. Demand for investment-grade private credit is rising as well, driven by insurance companies seeking excess spread and institutional investors looking for alternatives to publicly traded fixed income. In this industry, brand and scale are critical – wealth advisors are more likely to recommend products from established firms which have long, successful track records. Hence, it is likely that the major players will be getting an increasing portion of the pie moving forward. Supported by these tailwinds, we believe APO and KKR are well-positioned with a long runway ahead for continued AUM growth and compounding of earnings, as they broaden their product offerings and deepen distribution across both individual and institutional channels. We have thus added to our positions at what we believe to be reasonable valuations, and these are businesses we expect to own for many years, if not indefinitely. :contentReference[oaicite:2]{index=2}

BSD Analysis:
KKR is private markets at industrial scale, spanning private equity, credit, infrastructure, and real assets. Diversification smooths cycles, even if headlines focus on buyouts. Permanent capital vehicles give KKR flexibility when fundraising slows. Fee-related earnings are increasingly the anchor of valuation. Performance matters, but platform breadth reduces single-strategy risk. Leverage and deal timing always carry risk, especially late cycle. This is not a boutique PE shop anymore. It’s an alternative asset conglomerate with global reach. KKR compounds when it plays offense during downturns.

Pitch Summary:
Historically, alternative asset managers primarily served institutional investors (sovereign wealth funds, pension funds etc.) seeking exposure to alternative assets. However, individual investors, from high-net-worth individuals to mass-affluent clients, are now increasingly interested in this asset class (private equity, infrastructure, credit etc.), creating a market potentially as large as the institutional segment. The industry is also now on the cusp of being able to sell products to the 401(k) market, which holds an estimated $7 trillion in assets. Demand for investment-grade private credit is rising as well, driven by insurance companies seeking excess spread and institutional investors looking for alternatives to publicly traded fixed income. In this industry, brand and scale are critical – wealth advisors are more likely to recommend products from established firms which have long, successful track records. Hence, it is likely that the major players will be getting an increasing portion of the pie moving forward. Supported by these tailwinds, we believe APO and KKR are well-positioned with a long runway ahead for continued AUM growth and compounding of earnings, as they broaden their product offerings and deepen distribution across both individual and institutional channels. We have thus added to our positions at what we believe to be reasonable valuations, and these are businesses we expect to own for many years, if not indefinitely. :contentReference[oaicite:1]{index=1}

BSD Analysis:
Apollo thrives where complexity scares traditional investors. Its credit-heavy focus generates steady fee income even when private equity cycles cool. Insurance float through Athene provides permanent capital, which is the real strategic advantage. Scale allows Apollo to structure deals others can’t touch. Earnings can look volatile, but fee-related earnings tell the cleaner story. Risk management is central, not decorative. This is not a bull-market-only asset manager. It’s a capital machine built for dislocation. Apollo works best when markets get uncomfortable.

Pitch Summary:
The author examines Hologic’s pending acquisition by Blackstone and TPG, which includes a $76 per-share cash payment plus a $3 contingent value right linked to Breast Health segment revenues. While the stock trades at a small spread to the offer and the CVR appears “free,” the author argues the milestones look extremely difficult to hit. The Breast Health division has posted year-over-year declines for the past year, making the required 6–7% annual growth rates appear unrealistic. Even though the downside to pre-announcement trading levels is modest, the CVR’s low probability of payout and potential regulatory risks reduce the attractiveness of the setup. The author also notes that in large-cap M&A the market’s pricing is often accurate, contributing to their skepticism. Overall, despite superficially limited downside, the author concludes the opportunity is not compelling.

BSD Analysis:
The structure resembles a classic low-risk merger-arbitrage setup with an embedded out-of-the-money optionality kicker. The key issue is that CVRs tied to operational turnarounds—especially in device-heavy businesses like breast imaging—tend to have poor realization rates unless clear catalysts exist. Hologic’s Breast Health segment has been pressured by capital budget cycles, slower replacement demand, and post-COVID normalization, making near-term reacceleration difficult to underwrite. Achieving mid-single-digit growth consistently over two years would likely require either a new product cycle or a major improvement in hospital spending conditions. Regulatory review is another non-trivial variable, as private-equity takeovers of large med-tech assets can attract heightened scrutiny, and any delays would erode the risk-reward further. In this context, the tight merger spread reflects confidence in deal closure but also suggests the CVR is priced close to zero because the market sees low odds of success. Without a clearer operational inflection in Breast Health, the thesis lacks an asymmetric payoff profile.```

Actual Post Content:
Any thoughts on $HOLX “free” CVR setup? HOLX is a $17bn mcap company being acquired by Blackstone and TPG for $76/share plus a $3 CVR tied to sales performance in one of the segments. The stock currently trades at about a 3% spread to the cash offer, with the CVR effectively “free.” Moreover, the downside to pre-announcement levels is only about 10%. Despite the size of the deal, free CVR + limited downside made me want to take a closer look at this. The CVR payouts depend on revenue growth in the Breast Health segment over the next two years. The main issue is that the CVR payout looks very difficult to achieve. The Breast Health segment has seen meaningful YoY sales declines over the past 12 months. To earn both CVR milestones ($1.50/share for each year), the segment would need to grow roughly 6–7% annually, which looks highly unlikely. So even if the CVR is effectively free, it doesn’t seem compelling to get involved. And all that assumes there’s no regulatory risk, or that it’s minimal, something I’m not entirely certain of. That said, my knowledge of the business is limited as I’ve only recently started looking into it, so take this with a grain of salt. Moreover, I tend to assume the market is generally right when it comes to large-cap M&A, which adds to my skepticism here. Anyways, if you’ve looked at the case more closely and see the CVR targets as more achievable, I’d be interested to hear your thoughts.

URL: https://x.com/InvestSpecial/status/1982952953557483870

Pitch Summary:
The author argues that Galaxy Digital’s new $1.15B exchangeable senior note offering is a highly strategic move designed to finance major AI data center expansion. They believe the company expects approval of another 800MW at its Helios site, and that the capital raise—combined with an earlier $325M investment—should fully fund the equity required to build the second 800MW tranche. The first 800MW project with CoreWeave is estimated to cost $7B, funded with 20% equity and 80% debt, and could deliver roughly $900M of EBITDA by 2028. Applying a 25× multiple, the author sees ~$40/share in equity value from the first tranche alone, with similar economics on a second tranche doubling that potential. Because the notes are exchangeable and not straight equity, the author believes dilution is manageable and repayment optionality exists. Overall, the capital raise accelerates timelines, enhances future cash flow potential, and positions Galaxy Digital as a leading AI data center operator.

BSD Analysis:
Galaxy Digital’s strategy reflects a broader convergence of digital infrastructure, AI compute demand, and institutional crypto-scale capital deployment. Financing large-scale power infrastructure for AI presents a fundamentally different earnings profile versus Galaxy’s legacy trading and asset-management operations, potentially smoothing volatility and improving the company’s multiple. The economics described—high-capex, high-EBITDA, long-duration assets—mirror tier-one data center projects where capital intensity is rewarded through long-term contracted cash flows. However, execution risk is substantial: permitting, grid access, construction timelines, and interest-rate sensitivity could materially impact returns. Funding both 800MW tranches concurrently front-loads risk but accelerates value realization if managed effectively. The reliance on aggressive multiples (25×) presumes a continued scarcity premium for AI-ready infrastructure; any normalization would compress expected equity value. Still, if Galaxy succeeds in scaling into AI data center infrastructure while retaining optionality through exchangeable debt, the business mix could shift toward more stable, higher-quality earnings.```

Actual Post Content:
$GLXY raises up to $1.15B in an exchange senior note offering - to me this makes complete sense and is extremely bullish. I believe management is doing this with the expectation for the next 800MW of power to be approved at Helios. $1.15B + 325M (sold to Capital Group) will give them the enough equity to build out the second 800MW tranche. With CoreWeave the first 800MW will cost ~$7B in CapEx planning to be funded with 20% equity and 80% debt. In 2028 they will be generating at the low end ~$900M in EBITDA, using a 25x multiple (Goldman used a multiple of 25x, $DLR and $EQIX trade at 20-25x but these are data center 1.0 players not purpose built for AI) we get $900M * 25 = $22.5B in enterprise value, subtract the $7B CapEx bill and that is $15.5B in Equity Value (~$40/share). So if they can get similar economics on the next 800MW that is another ~$40/share. This offering gives them the capital to build both 800MW tranches of power out concurrently massively pulling forward cashflows and further cementing $GLXY as a leader in the AI Data Center space. This is an exchangeable note so Galaxy can choose to pay this back in shares or cash / a combination of them both! So it doesn't necessarily mean dilution, the note is due 2031 so they will be cash flowing plenty by then to figure out the best way to pay back the note. I think this is incredibly bullish and I am eagerly awaiting communications from @novogratz / @jonathan_mg27 on the use of proceeds here + the next 800MW approval at Helios! (Above is my best guess).

URL: https://x.com/FloodCapital/status/1982924534777831877

Pitch Summary:
The author presents CMSG as a heavily mispriced, illiquid Bitcoin miner trading below its net cash and BTC holdings, i.e., at a negative enterprise value. The company holds roughly $60m in cash and 340 BTC plus some PPE, giving book value around $101m versus a market cap in the mid-$90m range, despite no debt. He argues that CMSG’s model structurally compounds BTC per share: instead of constantly selling mined coins and issuing equity to refresh rigs, under Murray Stahl’s guidance they operate in a way that avoids the typical dilutive treadmill of conventional miners. Recent quarterly results showed the company adding 5.9 BTC and 631 LTC to the balance sheet with only about $4m of employed capital, implying ~18% quarterly ROCE and ~20% quarterly returns on capital. Given that book value per share is compounding quickly and ROICs are strong, he contends the stock should trade at a clear premium to book, not a discount, and certainly not at negative EV. He notes that sister company WELX, running a similar playbook, already trades at a premium to book, underscoring how anomalous CMSG’s valuation is. The main reason for the dislocation, in his view, is lack of discovery and a tiny natural buyer base (Bitcoin value stock, illiquid OTC), not fundamentals. A later update emphasizes that the stock has become even cheaper, at only 75% of cash plus BTC and barely above cash alone, reinforcing his conviction in the upside.

BSD Analysis:
This is essentially a balance sheet plus capital allocation story wrapped in a Bitcoin proxy. CMSG’s assets are transparent and largely liquid — cash and BTC — which makes a negative EV particularly striking relative to the quality of its reported ROIC. The claimed ~18–20% quarterly ROCE on a small capital base, if repeatable, translates into extraordinary compounding of book value per share and BTC per share, which should command at least some premium to static BTC exposure. The operating model, influenced by Murray Stahl/Horizon Kinetics, explicitly tries to solve the classic miner problem of perpetual dilution to fund capex, which, if executed well, can create a structurally better vehicle than most public miners. However, investors must underwrite several layers of risk: operational execution, hosting and energy costs, the durability of current ROICs as the asset base scales, and of course underlying BTC price volatility. Liquidity and governance are also non-trivial considerations for an OTC name where a few holders and related parties have meaningful influence and price discovery is poor. On valuation, even a modest premium to adjusted book (cash + BTC) would imply substantial upside from a starting point below those asset values, but the catalyst set is soft — better disclosure, eventual up-listing, or continued compounding could slowly attract more sophisticated capital. In practice, this kind of situation tends to remain mispriced longer than seems rational, so position sizing and time horizon discipline are key.```

Actual Post Content:
1/ $CMSG is a quirky and very mispriced OTC stock for small accounts with potentially explosive upside over time - this could double today and still look attractive (NB: very illiquid!). Consensus Mining is another Horizon Kinetics related BTC miner. IPO'd this summer in darkness, stock has found itself completely dislocated as lack of discovery has led to no bid for any legacy holders looking for some liquidity (shares have traded as high as $80, but are now at $40 on no news). Even if you're a Bitcoin skeptic, the numbers are hard to ignore: ROICs have been absurdly good, yet the enterprise value is negative (I.e. it trades at a discount to its cash and BTC holdings) - Market cap is ~$94 at current ask; - vs. book value of ~$101m, comprised mainly of $60m cash, 340 BTC worth $39 at current spot ($115K), $4m of PPE, less $5m DTLs (gains on BTC). No debt. Where should it trade? Clearly at a material premium to book value...because CMSG's model generates sustainable growth in BTC/share - i.e. it accretively creates BTC, giving shareholders upside to both price and quantity. By definition, that should be worth a premium to simply buying BTC. Indeed, sister company $WELX (see QT), running an identical playbook, itself trades at a premium to book despite being smaller, even less liquid, and poorly capitalized... 2/ Under guidance of Murray Stahl, CMSG has developed a method to avoid the pitfalls of the conventional approach to mining which often requires BTC rewards to be sold (and equity issued) to fund replacement of rapidly depreciating equipment. The traditional model is dilutive. 3/ The ROICs unequivocally validate the merits of this approach. E.g. in the most recent Q, CMSG added 5.9 BTC and 631 LTC to its balance sheet. At today's spot, that accumulation is worth $741K, generated with merely $4m of employed capital. In other words, an 18% ROCE in a 4/ Suffice to say that a business growing BVPS at this clip and generating ~20% quarterly returns on its capital base has no business trading below book value. Indeed, even terribly dilutive miners that have never earned their cost of capital fetch a multiple of book. Again, Few will care because there's not many natural investors for this (a Bitcoin value stock, illiquid, OTC, etc.) I've ever seen ROICs like this attached to negative enterprise value. Stahl's been adding himself. Now trading at 75% of cash + BTC, and only 15% premium to cash. Hilarious. $CMSG

URL: https://x.com/ragingbullcap/status/1983198956566745239

Pitch Summary:
Kenvue is the former J&J Consumer Health business, housing durable household brands across Self Care, Skin Health & Beauty, and Essential Health, but it has traded at a persistent discount since the 2023 spin as organic growth and execution disappointed. The stock has been hit by a cluster of negatives—reduced guidance and a CEO firing, headline-driven anxiety around Tylenol and pregnancy claims, and a newly filed UK talc lawsuit without JNJ indemnification—pushing sentiment to trough levels and compressing multiples. The pitch argues the market is overreacting to both legal narratives, since the scientific case for Tylenol causation is weak and the UK system is less punitive than U.S. talc litigation, with any potential payout manageable for the balance sheet. Activist involvement and board refresh increase the odds of operational change, portfolio rationalization, and a more credible turnaround plan under a new CEO. With the shares priced well below peers on both P/E and EV/EBITDA, even modest evidence of stabilization and margin/brand execution can drive multiple expansion. A base case target assumes partial re-rating to a still-discounted sector multiple over the next 6–12 months, with additional upside if strategic review outcomes include asset sales or a break-up. Risks include further international talc actions, a sharper consumer slowdown, and tariff-driven cost pressure, but the thesis views the current price as already discounting an overly harsh scenario.

BSD Analysis:
Kenvue is a post-spin consumer health business where weak execution and multiple headline risks have driven an unusually pessimistic valuation versus staples peers. Activist involvement has already forced leadership change and a strategic review, creating a credible catalyst for operational fixes, portfolio rationalization, or an asset-level transaction. The market is also over-discounting the Tylenol/autism narrative and the UK talc lawsuit, which are real uncertainties but look manageable relative to KVUE’s cash flow and balance sheet. Upside comes from a new CEO resetting expectations, improving Skin Health & Beauty execution, and narrowing the peer multiple gap as the turnaround becomes measurable. Key catalysts are CEO selection/strategy updates, quarterly results that show stabilization in volumes and margins, and any clarity on litigation scope and timing. Risks include additional international talc claims, tariff-driven cost pressure that is harder to pass through, and a consumer slowdown that delays a top-line inflection.

Pitch Summary:
Advance Auto Parts is a U.S. auto parts retailer serving both DIY and professional (DIFM) customers, now in the midst of a major turnaround under CEO Shane O’Kelly (since Sept 2023). The thesis is that prior failed turnarounds created deep skepticism, but this management team has taken decisive, structural actions: selling Worldpac to improve liquidity, exiting ~500 underperforming stores, and rationalizing the distribution footprint to improve service levels and reduce costs. The company is shifting toward a hub-and-spoke distribution model aimed at faster delivery times and better parts availability, with a path to meaningful margin recovery. Street expectations remain conservative relative to management’s 2027 operating margin target (~7%), setting up positive estimate revisions as execution proves out. A near-term tailwind is tariff-driven inflation, which can lift same-store sales in a relatively inelastic category with attractive flow-through as operations stabilize. Valuation is discounted versus peers on an EV/EBITDA basis, implying room for multiple expansion if the turnaround gains credibility. Catalysts include quarterly earnings that show comping and margin progress, further supply-chain execution milestones, and eventual resumption of capital return as credit profile improves. Key risks include execution slippage, competitive response from ORLY/AZO, and macro-driven demand volatility.

BSD Analysis:
AAP is being priced like a structurally broken retailer when it is more accurately a deeply wounded but fixable operator undergoing its first credible operational reset in a decade. The market is anchoring on historical underperformance versus ORLY/AZO and extrapolating execution failure, while missing that the current management team is shrinking the footprint, simplifying the network, and explicitly prioritizing service-level recovery over vanity growth. Business quality is not the issue—auto parts demand remains inelastic, pricing power exists in inflationary regimes, and the category structurally rewards scale once logistics stop working against you. The blind spot is incremental margin math: with EBITDA margins near trough, even modest service improvements and cost takeout can drive outsized earnings leverage without heroic comp assumptions. Valuation looks “cheap” because earnings are broken, but the reality is that the stock only needs to re-rate from “permanent mess” to “second-tier but functional” to justify meaningful upside. Governance has improved materially, with capital allocation sequenced correctly toward liquidity, balance-sheet repair, and operational credibility before buybacks. Position sizing should reflect execution risk and competitive pressure, but the skew is attractive because downside is largely priced while upside is driven by measurable KPIs rather than sentiment. The thesis fails if distribution metrics and delivery times do not improve over the next 12–18 months, confirming the issues are cultural rather than structural.

Pitch Summary:
Sprouts Farmers Market is a specialty grocer focused on “better-for-you” food, with a differentiated assortment skewed toward fresh, natural, and private-label products that continues to take share within U.S. food retail. While near-term same-store sales face difficult comparisons, the company is quietly improving new-store economics and accelerating unit growth, positioning it as one of the few credible growth stories in staples. Sprouts’ small-box, Trader Joe’s–adjacent format drives attractive returns on invested capital and supports a long runway toward 1,000+ stores nationally. The market is currently fixated on comp deceleration and grocery margin anxiety, discounting the durability of Sprouts’ category tailwinds and store-level profitability. Capital returns via buybacks are becoming a meaningful EPS lever alongside operating growth. Valuation reflects skepticism around near-term comps rather than normalized earnings power over a multi-year horizon. Key risks include competitive pricing pressure from larger grocers and a failure of comps to reaccelerate as the base resets.

BSD Analysis:
SFM is a grocery name rolling into comp hell, when it is actually a category leader in one of the few growing food segments. Business quality is driven by differentiated assortment and improving store cohorts. What the market is missing is the runway to 1,000+ stores with accelerating unit economics. Valuation discounts near-term comps rather than long-term EPS power. Governance and capital return amplify upside. Position sizing should reflect competitive intensity. The thesis breaks if comps fail to normalize.

Pitch Summary:
ServiceNow underperformed during the quarter after the company provided guidance that investors viewed as cautious, and caused concern that renewal deals from large clients were being pushed out. The company’s AI innovations are gaining traction and support the company’s strategic positioning as a next-gen workflow and AI orchestration platform.

BSD Analysis:
ServiceNow is the automation engine of the modern enterprise — workflows, IT, HR, ops, and now AI orchestration. The platform is sticky, mission-critical, and expanding horizontally with frightening efficiency. Enterprise customers don’t just buy ServiceNow; they build on top of it. The company’s AI and governance offerings are turning it into the central nervous system of corporate IT. Growth remains elite, margins are expanding, and renewal rates are absurd. ServiceNow is one of the purest large-cap software compounders on the planet.